# Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

> **NCT00780143** · PHASE1,PHASE2 · TERMINATED · sponsor: **PharmaMar** · enrollment: 3 (actual)

## Conditions studied

- Relapsed/Refractory Leukemia

## Interventions

- **DRUG:** Plitidepsin plus Cytarabine

## Key facts

- **NCT ID:** NCT00780143
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2018-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780143, "Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00780143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*